231 results
Page 3 of 12
6-K
EX-99.1
04z a49y2pov37
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
EX-2.1
3t1 67czc0
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
EX-2.1
m7ih592661u 3n1u
8 Jul 22
Current report (foreign)
8:58am
6-K
EX-99.1
38xtqlcvpiglxfa80
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
EX-99.1
vxf6zw2dm plryz9m
31 Mar 22
Portage Biotech Provides Update on Clinical-Stage and Development Programs
8:00am
20-F/A
53zr73c7ulx396i
3 Mar 22
Annual report (foreign) (amended)
6:57pm
6-K
EX-99.1
f0q75r xs7eyfy
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.2
o1mxfft7pxswr2gwlm3
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.1
ryso3ktq66
25 Feb 22
Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year
12:00am
6-K
EX-99.1
lo3f1
15 Feb 22
Portage Biotech Announces New Appointments to its Management Team and Board of Directors
8:00am
6-K
EX-99.2
zh99rvm
23 Nov 21
Current report (foreign)
4:30pm
6-K
EX-99.1
fe9vjqh e69
23 Nov 21
Current report (foreign)
4:30pm
6-K
EX-99.1
oj9kb
23 Nov 21
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
8:00am
6-K
lp3yk2 ab3
30 Aug 21
Current report (foreign)
5:21pm
6-K
EX-99.2
w2aig835g jm4q7b
30 Aug 21
Current report (foreign)
5:21pm
6-K
EX-99.1
wj29 vd0vi
30 Aug 21
Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
8:00am
6-K
EX-99.1
cptax0i ci3vro
12 Aug 21
Portage Biotech Issues Letter to Shareholders
10:01am
6-K
EX-99.1
o0mzv7y dy0e
28 Jul 21
Current report (foreign)
9:37am
SUPPL
xzz3pr1we2tc wz9me
24 Jun 21
Supplemental materials (foreign)
5:27pm